Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Immuno-epigenetic escape of cancer stem cells

The net effect of type I interferon (IFN-I) signaling on tumor control depends on various factors, including the potential engagement of adaptive anticancer immunity. New findings delineate a targetable epigenetic mechanism by which suboptimal IFN-I signaling promotes tumor progression in the context of cancer stem cell expansion and immunoevasion.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Suboptimal ICD induction coupled to CSC expansion by IFN-I-driven KDM1B activation.


  1. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Nat. Rev. Immunol. 15, 87–103 (2015).

    Article  CAS  Google Scholar 

  2. Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Nat. Immunol. 23, 487–500 (2022).

    Article  CAS  Google Scholar 

  3. Musella, M. et al. Nat. Immunol. (2022).

    Article  PubMed  Google Scholar 

  4. Sistigu, A. et al. Nat. Med. 20, 1301–1309 (2014).

    Article  CAS  Google Scholar 

  5. Yamazaki, T. et al. Nat. Immunol. 21, 1160–1171 (2020).

    Article  CAS  Google Scholar 

  6. Rodriguez-Ruiz, M. E. et al. Oncoimmunology 8, e1655964 (2019).

    Article  Google Scholar 

  7. Weichselbaum, R. R. et al. Proc. Natl Acad. Sci. USA 105, 18490–18495 (2008).

    Article  CAS  Google Scholar 

  8. Palucka, A. K. & Coussens, L. M. Cell 164, 1233–1247 (2016).

    Article  CAS  Google Scholar 

  9. Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cancer Cell 34, 361–378 (2018).

    Article  CAS  Google Scholar 

  10. Hopfner, K. P. & Hornung, V. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).

    Article  CAS  Google Scholar 

  11. Rehwinkel, J. & Gack, M. U. Nat. Rev. Immunol. 20, 537–551 (2020).

    Article  CAS  Google Scholar 

  12. Bayik, D. & Lathia, J. D. Nat. Rev. Cancer 21, 526–536 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Lorenzo Galluzzi or Guido Kroemer.

Ethics declarations

Competing interests

L.G. declares having held research contracts with Lytix Biopharma and Promontory, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. G.K. declares having held research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sotio, Tollys, Vascage and Vasculox/Tioma, has received consulting/advisory honoraria from Reithera, is on the Board of Directors of the Bristol Myers Squibb Foundation France, is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio, and is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders, including patents licensed to Bayer (WO2014020041-A1, WO2014020043-A1), Bristol-Myers Squibb (WO2008057863-A1), Osasuna Therapeutics (WO2019057742A1), PharmaMar (WO2022048775-A1), Raptor Pharmaceuticals (EP2664326-A1), Samsara Therapeutics (GB202017553D0 and GB202017030D0), and Therafast Bio (EP3684471A1).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Galluzzi, L., Kroemer, G. Immuno-epigenetic escape of cancer stem cells. Nat Immunol 23, 1300–1302 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer